P
Positrigo
Developing a brain positron emission tomography system to offer functional brain imaging to everyone at a more accessible price.
About Positrigo
Developer of positron emission tomography scanners designed to improve the diagnosis of Alzheimer's disease. The company's scanner includes an application-specific brain system that cost just a tenth of current PET machines and footprint is less than two square meters and is much more mobile than conventional machines, enabling doctors to diagnose neurodegenerative diseases early using experimental particle physics easily and cheaply.
Source: Dealroom company dataAt a glance
- Founded
- 2018
- Headquarters
- Zurich, Switzerland
- Sector
- Health Tech & Medtech
Knowledge graph
More headlines
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed3 investors entered at this stage
Venture Kick
European Innovation Council
Innosuisse
Series A6 investors entered at this stage
EIC Fund- GVGreat Filter Venture
ZKB - Zürcher Kantonalbank
4FOX Ventures
Fairway Asset Management
ETH Foundation
Series B and later3 investors entered at this stage
SICTIC
HealthCap
Navivo Capital
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Positrigo on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Positrigo on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.